JW China and foreign pharmaceutical companies, first quarter sales of 198.5 billion won · net profit of 28.5 billion won Rapid growth

JW China and Foreign Pharmaceuticals delivered a dual improvement in profitability and sales growth in the first quarter of 2026. Centered on professional pharmaceuticals, the company expanded its scale, while sales of general pharmaceuticals also rose significantly, with both operating profit and net profit recording double-digit growth rates.

JW China and Foreign Pharmaceuticals announced on the 12th that, based on separate financial statements, operating profit for this year’s first quarter was 31.7 billion won, up 40.4% from the same period last year. In the same period, sales revenue was 198.5 billion won, up 8.1%; net profit was 28.5 billion won, up 62.3%. The increase in profit outpaced the increase in sales, which can be interpreted as improved profitability driven by changes in the product mix and sales efficiency.

From the perspective of business divisions, the core driver of the improvement was professional pharmaceuticals. Sales of professional pharmaceuticals reached 164.9 billion won, up 8.4%. Of this, the sales of “Lipalojie,” a modified new combination drug for treating dyslipidemia, were 28.3 billion won, up 21.0%; sales of “Hanlibr a,” a hemophilia treatment drug, were 23.1 billion won, up 59.8%. The joint growth of chronic-disease treatments and products related to rare diseases has made the company’s core business base more solid.

The general pharmaceuticals segment also showed a very notable growth rate. Sales of general pharmaceuticals were 15.0 billion won, up 41.1%. The “Friends” eye-care brand that consumers can purchase directly at pharmacies and other retailers recorded sales of 5.7 billion won, up 56.0%; sales of the wound-management bandage “Hy-Mom” also reached 1.4 billion won, up 29.3%. In addition to professional pharmaceuticals, sales of life-oriented products close to everyday needs were also expanded, which is important for diversifying revenue sources.

The company stated that it will, based on creating stable earnings, expand R&D investment and strengthen a virtuous-cycle structure connected to ensuring future growth momentum. In the pharmaceutical industry, performance improvements typically enhance R&D capabilities, which in turn translates into competitiveness in new drugs and improved drugs—this structure is crucial. If, going forward, the expansion of sales of core professional pharmaceuticals and the strengthening of general pharmaceutical brands can be sustained, this trend may develop in a direction that broadens the foundation for medium- and long-term growth.